Evidence map›Paper›PMID 22517310›Full record

ArticleCancer2012

Primary care providers' perspectives on discontinuing prostate cancer screening.

Craig E Pollack, Elizabeth A Platz, Nrupen A Bhavsar, Gary Noronha, Gene E Green, Sean Chen, H Ballentine Carter

Abstract read
In one paragraph

Article in Cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Similar perspectives on prostate cancer screening value and new guidelines across patient demographic and PSA level subgroups: A qualitative study.Health expectations : an international journal of public participation in health care and health policy · 2017
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Craig E PollackDivision of General Internal Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA. cpollac2@jhmi.edu
Elizabeth A Platz
Nrupen A Bhavsar
Gary Noronha
Gene E Green
Sean Chen
H Ballentine Carter

Funding

Research Infrastructure for the Hopkins Population CenterR24HD042854 · NICHD · JOHNS HOPKINS UNIVERSITY · PI HAO, LINGXIN · 2003 to 2017
$5.1M
Training in Comparative Effectiveness Research to Improve Family Health ServicesT32HS019488 · AHRQ · JOHNS HOPKINS UNIVERSITY · PI DUGGAN, ANNE K · 2010 to 2010
$866k
A Network Analytic Approach to Modeling Variation in Prostate Cancer CareK07CA151910 · NCI · JOHNS HOPKINS UNIVERSITY · PI POLLACK, CRAIG EVAN · 2011 to 2015
$780k
AHRQ HHS T32 HS019488NCI NIH HHS K07 CA151910NICHD NIH HHS R24 HD042854
6 · The paper itself

Abstract

backgroundClinical guidelines recommend against routine prostate-specific antigen (PSA) screening for older men and for those with lower life expectancies. The authors of this report examined providers' decision-making regarding discontinuing PSA screening.

methodsA survey of primary providers from a large, university-affiliated primary care practice was administered. Providers were asked about their current screening practices, factors that influenced their decision to discontinue screening, and barriers to discontinuing screening. Bivariate and multivariable logistic regression analyses were used to examine whether taking age and/or life expectancy into account and barriers to discontinuing were associated with clinician characteristics and practice styles.

resultsOne hundred twenty-five of 141 providers (88.7%) participated in the survey. Over half (59.3%) took both age and life expectancy into account, whereas 12.2% did not consider either in their decisions to discontinue PSA screening. Providers varied in the age at which they typically stopped screening patients, and the majority (66.4%) reported difficulty in assessing life expectancy. Taking patient age and life expectancy into account was not associated with provider characteristics or practice styles. The most frequently cited barriers to discontinuing PSA screening were patient expectation (74.4%) and time constraints (66.4%). Black providers were significantly less likely than nonblack providers to endorse barriers related to time constraints and clinical uncertainty, although these results were limited by the small sample size of black providers.

conclusionsAlthough age and life expectancy often figured prominently in decisions to use screening, providers faced multiple barriers to discontinuing routine PSA screening.

Indexed as

Early Detection of CancerPractice Patterns, Physicians'Age FactorsDecision MakingFemaleHealth Planning GuidelinesHumansLife ExpectancyMaleMass ScreeningPractice Guidelines as TopicPrimary Health CareProstate-Specific AntigenProstatic NeoplasmsSurveys and QuestionnairesProstate-Specific Antigen

Identifiers

PMID22517310
PMCPMC3427393

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.